Clear All
760 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Palbociclib Ibrance 125 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2015 In Use
NA Anastrozole Arimidex 0.5 mg Hormonal Therapy Aromatase Inhibitor Yes 1995 In Use
NA Nilotinib Tasigna 200 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2007 In Use
Niraparib and Abiraterone Akeega Multiple Chemotherapy Androgen Receptor Inhibitor, Enzyme Inhibitor CYP 17, PARP Yes 2023 In Use
NA Pirtobrutinib Jaypirca Multiple Chemotherapy Tyrosine Kinase Inhibitor BTK Yes 2023 In Use
NA Afatinib Gliotrif 40 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2013 In Use
NA Duvelisib Copiktra 15mg, 25mg Chemotherapy Enzyme Inhibitor PI3K Yes 2018 In Use
NA Darolutamide Nubeqa 300mg Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Yes 2019 In Use
NA Estramustine Phosphate Sodium Emcyt 140 mg Chemotherapy Alkylating Agent Nitrogen Mustard Yes 1981 In Use
Revumenib Revuforj 25mg, 110mg, 160mg Chemotherapy Enzyme Inhibitor KMT2A Yes 2024 In Use
NA Afatinib Gliotrif 20 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2013 In Use
NA Apalutamide Erleada 60mg Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Yes 2018 In Use
NA Fluprednisolone Valerate Alphadrol 1.5 mg Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Yes In Use
NA Abemaciclib Verzenio 200 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Carmustine wafer Gliadel 7.7mg Chemotherapy Alkylating Agent Nitrosourea No 2012 In Use
NA Anagrelide Agrylin 1mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
N/A Ensartinib ENSACOVE 25mg, 100mg Chemotherapy Tyrosine Kinase Inhibitor ALK, ROS1, MET Yes 2025 In Use
NA Enasidenib mesylate Idhifa 50 mg Chemotherapy Enzyme Inhibitor IDH2 Yes 2017 In Use
Inavolisib Itovebi 3mg, 9mg Chemotherapy Enzyme Inhibitor PI3K⍺ Yes 2024 In Use
NA Avapritinib Ayvakit 25mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Trametinib Mekinist 2 mg Chemotherapy MEK Inhibitor BRAF Yes 2013 In Use
NA Nilotinib Tasigna 150 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2007 In Use
NA Naldemedine Symproic 0.2mg Ancillary Therapy Opioid Antagonist Yes 2018 In Use
NA Acalabrutinib Calquence 100 mg Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Yes 2017 In Use
NA tretinoin Vesanoid 10 mg Hormonal Therapy Immunomodulator Retinoic Acid Derivative Yes 1995 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.